Contrast medium nephrotoxicity after renal artery and coronary angioplasty.
BACKGROUND
Renal dysfunction induced by iodinated contrast medium (CM) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty (PTRA).


OBJECTIVE
To compare the susceptibility to nephrotoxic effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention (PCI).


METHODS
A total of 33 patients successfully treated with PTRA (PTRA group, mean age 70+/-12 years, 23 female, basal creatinine 1.46+/-0.79, range 0.7-4.9 mg/dl) were compared with 33 patients undergoing successful PCI (PCI group), matched for basal creatinine (1.44+/-0.6, range 0.7-3.4 mg/dl), gender, and age. In both groups postprocedural (48 h) serum creatinine was measured.


RESULTS
Postprocedural creatinine level decreased nonsignificantly in the PTRA group (1.46+/-0.8 vs. 1.34+/-0.5 mg/dl, P=NS) and increased significantly in the PCI group (1.44+/-0.6 vs. 1.57+/-0.7 mg/dl, P<0.02). Changes in serum creatinine after intervention (after-before) were significantly different between the PTRA and PCI groups (-0.12+/-0.5 vs. 0.13+/-0.3, P=0.014). This difference was not related to either a different clinical risk profile or to the volume of CM administered.


CONCLUSIONS
In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients. The effectiveness of PTRA on renal function seems to be barely influenced by CM toxicity.
Marraccini
Paolo
P
CNR Institute of Clinical Physiology of Pisa, Italy. paolomar@ifc.cnr.it
Bianchi
Massimiliano
M
Fommei
Enza
E
Palmieri
Cataldo
C
Ciriello
Giuseppe
G
Ciardetti
Marco
M
Mazzarisi
Alessandro
A
Djukic
Goran
G
L'Abbate
Antonio
A
D000368:Aged; D017130:Angioplasty; D015906:Angioplasty, Balloon, Coronary; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D003287:Contrast Media / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D004198:Disease Susceptibility; D005260:Female; D006801:Humans; D006978:Hypertension, Renovascular / Q000628:therapy*; D007479:Iopamidol / Q000009:adverse effects / Q000031:analogs & derivatives*; D007674:Kidney Diseases / Q000139:chemically induced*; D007677:Kidney Function Tests; D008297:Male; D012077:Renal Artery; D015607:Stents
D003287:Contrast Media; C057937:iomeprol; D003404:Creatinine; D007479:Iopamidol